<DOC>
	<DOCNO>NCT01534962</DOCNO>
	<brief_summary>Dose-ranging Phase II study test efficacy safety 3 dos Ranolazine ( low , intermediate high , give BID ) versus placebo maintain sinus rhythm successful electrical cardioversion patient persistent atrial fibrillation ( AFib ) . After successful cardioversion subsequent randomisation , patient report trans-telephonic EGCs daily basis central core ECG facility . Maximum treatment duration 112 day ( 16 week ) .</brief_summary>
	<brief_title>Ranolazine Atrial Fibrillation Following An ELectricaL CardiOversion</brief_title>
	<detailed_description>Patients persistent AFib screen eligibility undergo direct current cardioversion ( DCC ) . If DCC successful ( defined persistence sinus rhythm 2 h post-DCC ) patient meet inclusion criterion none exclusion criterion randomly assign treatment arm ( Ranolazine low , intermediate , high dose placebo , give BID ) . Transtelephonic ECG device ( TT-ECG ) use record AFib recurrence read Central ECG Core Laboratory . Any symptoms indicative AFib record patient diary . Study Visits hold screen ( Visit 1 ) , DCC randomisation ( Visit 2 ) , one week post DCC ( Visit 3 ) , 8 week treatment ( Visit 4 ) , end treatment ( Visit 5 ) . A safety follow-up telephone call hold 2 week end treatment . 12-Lead ECGs perform every visit . Safety evaluation include regular safety laboratory blood urine test , 12-lead ECGs continuous record adverse event . A double-dummy technique use ensure double-blind condition .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Male female patient 18 year old Patients persistent AF suitable electrical direct current cardioversion ( DCC ) A female childbearing potential may enrol provide negative pregnancy test baseline routinely use effective method birth control result low failure rate end study Able give write informed consent study related procedure Able attend visit schedule study Patients first diagnose AF patient paroxysmal AF Patients longstanding persistent AF permanent AF Patients known concurrent temporary secondary cause AF alcohol intoxication , pulmonary embolism , hyperthyroidism , pneumonia , hypoxemia , acute pericarditis myocarditis Patients undergone atrial catheter ablation AF Patients carry pacemaker Patients electrolytes imbalance may cause cardiac arrhythmia , e.g . potassium &lt; 3.5 mmol/L &gt; 5.5 mmol/L Patients contraindication Ranexa accord drugspecific product characteristic Patients take class I Class III antiarrhythmic agent within 3 day plan randomisation Patients take betablockers unless use stable dos least 2 week prior plan randomisation . Single dose Intravenous betablockers allow 10 hour plan randomisation Patients take Dronedarone oral Amiodarone within 2 week 3 month plan randomisation , respectively Patients history ECG abnormalities opinion Investigator render subject unsuitable trial , include history congenital family history long QT syndrome QTc interval â‰¥500 msec Screening Patients congestive heart failure NYHA grade III IV ; Patients serious intercurrent illness ( include psychiatric neurological disorder ) , opinion Investigator , incompatible protocol . Patients take Metformin total daily dose great 1000 mg . Patients take Simvastatin total daily dose great 20 mg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Ranolazine</keyword>
	<keyword>Arrhythmias , Cardiac</keyword>
	<keyword>Antiarrhythmic Agents</keyword>
	<keyword>Cardiac Electroversion</keyword>
	<keyword>Ranexa</keyword>
</DOC>